vs
Side-by-side financial comparison of National Storage Affiliates Trust (NSA) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
National Storage Affiliates Trust is the larger business by last-quarter revenue ($187.0M vs $177.4M, roughly 1.1× Pacira BioSciences, Inc.). National Storage Affiliates Trust runs the higher net margin — 12.2% vs 1.6%, a 10.6% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -1.6%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -2.4%).
National Storage Affiliates Trust is a U.S.-headquartered real estate investment trust focused on self-storage assets. It owns, operates and acquires self-storage facilities across dozens of U.S. states, offering secure storage solutions for residential and commercial customers.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
NSA vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $187.0M | $177.4M |
| Net Profit | $22.9M | $2.9M |
| Gross Margin | 72.5% | — |
| Operating Margin | 20.2% | 3.9% |
| Net Margin | 12.2% | 1.6% |
| Revenue YoY | -1.6% | 5.0% |
| Net Profit YoY | 36.8% | — |
| EPS (diluted) | $0.23 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $187.0M | $196.9M | ||
| Q3 25 | $188.7M | $179.5M | ||
| Q2 25 | $188.8M | $181.1M | ||
| Q1 25 | $188.4M | $168.9M | ||
| Q4 24 | $190.1M | $187.3M | ||
| Q3 24 | $193.6M | $168.6M | ||
| Q2 24 | $190.4M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $22.9M | — | ||
| Q3 25 | $18.4M | $5.4M | ||
| Q2 25 | $19.5M | $-4.8M | ||
| Q1 25 | $13.0M | $4.8M | ||
| Q4 24 | $16.7M | — | ||
| Q3 24 | $18.7M | $-143.5M | ||
| Q2 24 | $17.1M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 72.5% | 79.5% | ||
| Q3 25 | 70.7% | 80.9% | ||
| Q2 25 | 70.5% | 77.4% | ||
| Q1 25 | 70.7% | 79.7% | ||
| Q4 24 | 72.5% | 78.7% | ||
| Q3 24 | 72.8% | 76.9% | ||
| Q2 24 | 72.6% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 20.2% | 1.2% | ||
| Q3 25 | 15.8% | 3.5% | ||
| Q2 25 | 16.5% | 4.7% | ||
| Q1 25 | 11.0% | 1.2% | ||
| Q4 24 | 14.5% | 13.2% | ||
| Q3 24 | 15.8% | -82.8% | ||
| Q2 24 | 17.2% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 12.2% | — | ||
| Q3 25 | 9.8% | 3.0% | ||
| Q2 25 | 10.3% | -2.7% | ||
| Q1 25 | 6.9% | 2.8% | ||
| Q4 24 | 8.8% | — | ||
| Q3 24 | 9.7% | -85.1% | ||
| Q2 24 | 9.0% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.23 | $0.05 | ||
| Q3 25 | $0.17 | $0.12 | ||
| Q2 25 | $0.19 | $-0.11 | ||
| Q1 25 | $0.10 | $0.10 | ||
| Q4 24 | $0.19 | $0.38 | ||
| Q3 24 | $0.18 | $-3.11 | ||
| Q2 24 | $0.16 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.3M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $946.0M | $653.9M |
| Total Assets | $5.1B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $23.3M | $238.4M | ||
| Q3 25 | $26.3M | $246.3M | ||
| Q2 25 | $26.1M | $445.9M | ||
| Q1 25 | $19.3M | $493.6M | ||
| Q4 24 | $50.4M | $484.6M | ||
| Q3 24 | $69.9M | $453.8M | ||
| Q2 24 | $59.0M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $946.0M | $693.1M | ||
| Q3 25 | $973.1M | $727.2M | ||
| Q2 25 | $1.0B | $757.8M | ||
| Q1 25 | $1.0B | $798.5M | ||
| Q4 24 | $1.1B | $778.3M | ||
| Q3 24 | $986.9M | $749.6M | ||
| Q2 24 | $1.2B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $5.1B | $1.3B | ||
| Q3 25 | $5.1B | $1.3B | ||
| Q2 25 | $5.2B | $1.5B | ||
| Q1 25 | $5.3B | $1.6B | ||
| Q4 24 | $5.4B | $1.6B | ||
| Q3 24 | $5.4B | $1.5B | ||
| Q2 24 | $5.3B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $338.5M | — |
| Free Cash FlowOCF − Capex | $299.8M | — |
| FCF MarginFCF / Revenue | 160.3% | — |
| Capex IntensityCapex / Revenue | 20.7% | — |
| Cash ConversionOCF / Net Profit | 14.79× | — |
| TTM Free Cash FlowTrailing 4 quarters | $541.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $338.5M | $43.7M | ||
| Q3 25 | $100.2M | $60.8M | ||
| Q2 25 | $79.9M | $12.0M | ||
| Q1 25 | $85.6M | $35.5M | ||
| Q4 24 | $363.1M | $33.1M | ||
| Q3 24 | $105.7M | $53.9M | ||
| Q2 24 | $83.2M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $299.8M | $43.5M | ||
| Q3 25 | $88.0M | $57.0M | ||
| Q2 25 | $73.8M | $9.3M | ||
| Q1 25 | $79.9M | $26.9M | ||
| Q4 24 | $344.4M | $31.0M | ||
| Q3 24 | $101.8M | $49.8M | ||
| Q2 24 | $79.5M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 160.3% | 22.1% | ||
| Q3 25 | 46.6% | 31.7% | ||
| Q2 25 | 39.1% | 5.1% | ||
| Q1 25 | 42.4% | 15.9% | ||
| Q4 24 | 181.2% | 16.6% | ||
| Q3 24 | 52.6% | 29.6% | ||
| Q2 24 | 41.7% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 20.7% | 0.1% | ||
| Q3 25 | 6.5% | 2.2% | ||
| Q2 25 | 3.2% | 1.5% | ||
| Q1 25 | 3.0% | 5.1% | ||
| Q4 24 | 9.8% | 1.1% | ||
| Q3 24 | 2.0% | 2.4% | ||
| Q2 24 | 1.9% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 14.79× | — | ||
| Q3 25 | 5.44× | 11.20× | ||
| Q2 25 | 4.10× | — | ||
| Q1 25 | 6.59× | 7.37× | ||
| Q4 24 | 21.70× | — | ||
| Q3 24 | 5.65× | — | ||
| Q2 24 | 4.88× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NSA
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
